Cargando…

Resveratrol inhibits nonalcoholic fatty liver disease in rats

BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic st...

Descripción completa

Detalles Bibliográficos
Autores principales: Bujanda, Luis, Hijona, Elizabeth, Larzabal, Mikel, Beraza, Marta, Aldazabal, Pablo, García-Urkia, Nerea, Sarasqueta, Cristina, Cosme, Angel, Irastorza, Belen, González, Alberto, Arenas, Juan I
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547101/
https://www.ncbi.nlm.nih.gov/pubmed/18782455
http://dx.doi.org/10.1186/1471-230X-8-40
_version_ 1782159210315776000
author Bujanda, Luis
Hijona, Elizabeth
Larzabal, Mikel
Beraza, Marta
Aldazabal, Pablo
García-Urkia, Nerea
Sarasqueta, Cristina
Cosme, Angel
Irastorza, Belen
González, Alberto
Arenas, Juan I
author_facet Bujanda, Luis
Hijona, Elizabeth
Larzabal, Mikel
Beraza, Marta
Aldazabal, Pablo
García-Urkia, Nerea
Sarasqueta, Cristina
Cosme, Angel
Irastorza, Belen
González, Alberto
Arenas, Juan I
author_sort Bujanda, Luis
collection PubMed
description BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities.
format Text
id pubmed-2547101
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25471012008-09-23 Resveratrol inhibits nonalcoholic fatty liver disease in rats Bujanda, Luis Hijona, Elizabeth Larzabal, Mikel Beraza, Marta Aldazabal, Pablo García-Urkia, Nerea Sarasqueta, Cristina Cosme, Angel Irastorza, Belen González, Alberto Arenas, Juan I BMC Gastroenterol Research Article BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities. BioMed Central 2008-09-09 /pmc/articles/PMC2547101/ /pubmed/18782455 http://dx.doi.org/10.1186/1471-230X-8-40 Text en Copyright © 2008 Bujanda et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bujanda, Luis
Hijona, Elizabeth
Larzabal, Mikel
Beraza, Marta
Aldazabal, Pablo
García-Urkia, Nerea
Sarasqueta, Cristina
Cosme, Angel
Irastorza, Belen
González, Alberto
Arenas, Juan I
Resveratrol inhibits nonalcoholic fatty liver disease in rats
title Resveratrol inhibits nonalcoholic fatty liver disease in rats
title_full Resveratrol inhibits nonalcoholic fatty liver disease in rats
title_fullStr Resveratrol inhibits nonalcoholic fatty liver disease in rats
title_full_unstemmed Resveratrol inhibits nonalcoholic fatty liver disease in rats
title_short Resveratrol inhibits nonalcoholic fatty liver disease in rats
title_sort resveratrol inhibits nonalcoholic fatty liver disease in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547101/
https://www.ncbi.nlm.nih.gov/pubmed/18782455
http://dx.doi.org/10.1186/1471-230X-8-40
work_keys_str_mv AT bujandaluis resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT hijonaelizabeth resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT larzabalmikel resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT berazamarta resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT aldazabalpablo resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT garciaurkianerea resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT sarasquetacristina resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT cosmeangel resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT irastorzabelen resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT gonzalezalberto resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats
AT arenasjuani resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats